Opus Genetics
IRD
17 hedge funds and large institutions have $523K invested in Opus Genetics in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
11% more capital invested
Capital invested by funds: $470K → $523K (+$53K)
0.28% more ownership
Funds ownership: 1.54% → 1.82% (+0.28%)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$81.3K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$22.2K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$2.9K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$52 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.51K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 3 |
Morgan Stanley
New York
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $334K | +$81.3K | +9,358 | +25% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $99K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $47K | – | – | – |
|
|
CS
4
Credit Suisse
Zurich,
Switzerland
| $18K | +$22.2K | +2,550 | New |
|
5
BlackRock
New York
| $16K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $7K | -$5.51K | -634 | -40% |
|
|
7
Victory Capital Management
San Antonio,
Texas
| $2K | +$2.9K | +334 | New |
|
|
APA
8
American Portfolios Advisors
Holbrook,
New York
| $14 | – | – | – |
|
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -375 | Closed |
|
|
10
Morgan Stanley
New York
| – | -$17 | -2 | -6% |
|
|
11
Wells Fargo
San Francisco,
California
| – | +$52 | +6 | +120% |
|
12
Osaic Holdings
Scottsdale,
Arizona
| – | +$156 | +18 | New |
|
IRD Hedge Fund Activity: Q1 2020 in Review
17 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2020, worth a combined $523K — up 11% from $470K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IRD positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $81.3K. The largest seller was UBS Group, cutting an estimated $5.51K.
- 17 institutional investors held Opus Genetics (IRD) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $523K of Opus Genetics stock for Q1 2020, up 11% quarter-over-quarter.
- 3 funds opened new Opus Genetics positions in Q1 2020 and 1 closed out, a net change of +2 holders.
- The largest Opus Genetics buyer in Q1 2020 was Renaissance Technologies, an estimated $81.3K added.
- The largest Opus Genetics seller in Q1 2020 was UBS Group, an estimated $5.51K sold.
Based on aggregated 13F filings for Q1 2020.